Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBSQH9)

Drug Name

PBF-999 Drug Info

Synonyms

CHEMBL3942498; SCHEMBL15905362; BDBM247392; SB18883; US9447095, 42; 5-bromo-4-N-prop-2-ynyl-2-(1,2,4-triazol-1-yl)pyrimidine-4,6-diamine; 1620909-95-6

Indication

Disease Entry	ICD 11	Status	REF
Huntington disease	8A01.10	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

Cross-matching ID

PubChem CID: 77107498
TTD Drug ID: DMBSQH9

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A2a receptor (ADORA2A)	TTM2AOE	AA2AR_HUMAN	Antagonist	[3]
Phosphodiesterase 10A (PDE10)	TTJW4LU	PDE10_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Adenosine A2a receptor (ADORA2A)	DTT	ADORA2A	5.075	5.752	5.928	6.324
Phosphodiesterase 10A (PDE10)	DTT	PDE10A	5.313	4.436	5.65	5.516

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Huntington disease

ICD Disease Classification

8A01.10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Phosphodiesterase 10A (PDE10)	DTT	PDE10A	1.99E-01	-0.07	-0.21
Phosphodiesterase 10A (PDE10)	DTT	PDE10A	4.51E-01	-0.05	-0.32

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT02208934) Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT03786484) Study of PBF-999 in Solid Tumour Advanced Cancer. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of Palobiofarma.